Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Pharmaceuticals

Real-time Estimate Tradegate
Other stock markets
 12:59:24 15/05/2024 pm IST 		5-day change 1st Jan Change
32.44 EUR -0.69% Intraday chart for Daiichi Sankyo Co., Ltd. +1.92% +30.91%
08:06am IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court MT
07/05 Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost RE

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 33,04,011 48,16,951 61,79,276 51,36,821 92,44,546 1,03,80,258 - -
Enterprise Value (EV) 1 27,85,091 41,59,929 55,38,193 44,56,437 89,95,480 91,59,669 97,76,879 97,76,996
P/E ratio 35.4 x 37.3 x 82.3 x 76.7 x 84.7 x 45.6 x 52.7 x 40.3 x
Yield 1.37% 0.94% 0.84% 1.01% 0.62% 1.05% 1.11% 1.23%
Capitalization / Revenue 3.55 x 4.91 x 6.42 x 4.92 x 7.23 x 5.72 x 5.88 x 4.99 x
EV / Revenue 3 x 4.24 x 5.75 x 4.26 x 7.04 x 5.72 x 5.53 x 4.7 x
EV / EBITDA 21.4 x 21.7 x 45.7 x 33.9 x 47.8 x 33.8 x 32.5 x 25.4 x
EV / FCF 49.8 x 36.2 x 36.2 x 58.3 x -62.8 x 28.9 x 77.4 x 60.1 x
FCF Yield 2.01% 2.76% 2.76% 1.72% -1.59% 3.46% 1.29% 1.66%
Price to Book 2.64 x 3.69 x 4.86 x 3.8 x 6.39 x 5.43 x 6.29 x 5.88 x
Nbr of stocks (in thousands) 19,43,536 19,43,887 19,16,055 19,16,724 19,17,160 19,16,945 - -
Reference price 2 1,700 2,478 3,225 2,680 4,822 5,415 5,415 5,415
Announcement Date 25/04/19 27/04/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 9,29,717 9,81,793 9,62,516 10,44,900 12,78,478 16,01,700 17,66,816 20,80,778
EBITDA 1 1,29,874 1,91,411 1,21,177 1,31,270 1,88,369 2,71,234 3,01,077 3,85,388
EBIT 1 83,705 1,38,800 63,795 73,000 1,20,580 2,11,600 2,34,025 3,17,719
Operating Margin 9% 14.14% 6.63% 6.99% 9.43% 13.21% 13.25% 15.27%
Earnings before Tax (EBT) 1 85,831 1,41,164 74,124 73,500 1,26,854 2,37,200 2,43,351 3,30,815
Net income 1 93,409 1,29,074 75,958 67,000 1,09,188 2,00,700 1,94,640 2,57,135
Net margin 10.05% 13.15% 7.89% 6.41% 8.54% 12.53% 11.02% 12.36%
EPS 2 48.07 66.40 39.17 34.94 56.96 104.7 102.7 134.3
Free Cash Flow 1 55,925 1,14,928 1,52,961 76,490 -1,43,268 3,16,622 1,26,394 1,62,555
FCF margin 6.02% 11.71% 15.89% 7.32% -11.21% 19.77% 7.15% 7.81%
FCF Conversion (EBITDA) 43.06% 60.04% 126.23% 58.27% - 116.73% 41.98% 42.18%
FCF Conversion (Net income) 59.87% 89.04% 201.38% 114.16% - 157.76% 64.94% 63.22%
Dividend per Share 2 23.33 23.33 27.00 27.00 30.00 50.00 60.00 66.54
Announcement Date 25/04/19 27/04/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2020 S2 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2025 S2 2026 S1 2026 S2
Net sales 1 4,79,573 5,02,220 4,80,168 2,65,896 5,29,965 2,81,002 2,33,933 - 2,80,317 3,27,480 6,07,797 3,40,479 3,30,202 3,50,835 3,75,465 7,26,300 4,46,925 4,28,431 - 4,03,417 4,25,667 7,45,636 4,68,600 4,67,733 - - -
EBITDA 1 - - - - - - - - - - - - - - - - 1,14,454 33,427 - 1,10,400 56,200 - 83,300 47,200 - - -
EBIT 1 86,163 52,637 58,465 38,973 84,742 39,030 -50,772 - 34,382 61,198 95,580 31,551 -6,551 44,032 51,068 95,100 99,488 17,049 - 57,102 51,620 54,820 70,912 38,997 - - -
Operating Margin 17.97% 10.48% 12.18% 14.66% 15.99% 13.89% -21.7% - 12.27% 18.69% 15.73% 9.27% -1.98% 12.55% 13.6% 13.09% 22.26% 3.98% - 14.15% 12.13% 7.35% 15.13% 8.34% - - -
Earnings before Tax (EBT) 1 87,040 54,124 66,986 38,893 85,955 39,931 -52,386 - 29,415 61,850 91,265 36,185 -596 52,133 49,967 1,02,100 97,749 37,354 - 60,047 39,200 54,820 66,300 30,200 - - -
Net income 1 64,426 64,648 51,667 27,245 62,465 31,853 -27,318 - 18,851 39,458 58,309 28,391 22,488 57,013 39,987 97,000 66,558 37,136 - 50,630 44,159 43,308 56,990 34,900 - - -
Net margin 13.43% 12.87% 10.76% 10.25% 11.79% 11.34% -11.68% - 6.72% 12.05% 9.59% 8.34% 6.81% 16.25% 10.65% 13.36% 14.89% 8.67% - 12.55% 10.37% 5.81% 12.16% 7.46% - - -
EPS 2 33.15 - 26.57 14.21 32.59 16.62 -10.07 - 9.840 20.58 30.42 14.81 11.73 29.74 20.85 50.59 34.72 19.38 - 19.29 24.76 22.60 30.74 30.28 - - -
Dividend per Share 2 11.67 11.67 13.50 - 13.50 - - 13.50 - - 15.00 - - - 20.00 20.00 - 30.00 17.00 - 30.00 20.00 - 30.00 20.00 25.00 25.00
Announcement Date 31/10/19 27/04/20 30/10/20 29/10/21 29/10/21 31/01/22 27/04/22 27/04/22 29/07/22 31/10/22 31/10/22 31/01/23 27/04/23 31/07/23 31/10/23 31/10/23 31/01/24 25/04/24 - - - - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 5,18,920 6,57,022 6,41,083 6,80,384 2,49,066 5,55,812 6,03,378 6,03,262
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 55,925 1,14,928 1,52,961 76,490 -1,43,268 3,16,622 1,26,394 1,62,555
ROE (net income / shareholders' equity) 7.8% 10.1% 5.9% 5.1% 7.8% 12.8% 11.6% 13.6%
ROA (Net income/ Total Assets) 4.31% 6.7% 3.54% 3.41% 5.36% 7.95% 6.58% 8.75%
Assets 1 21,68,857 19,26,478 21,47,241 19,62,438 20,35,768 25,25,319 29,59,141 29,39,795
Book Value Per Share 2 643.0 672.0 664.0 705.0 754.0 880.0 861.0 921.0
Cash Flow per Share 2 71.80 101.0 68.80 65.30 92.30 136.0 132.0 143.0
Capex 1 36,108 31,936 31,245 62,736 71,539 88,321 86,333 1,08,359
Capex / Sales 3.88% 3.25% 3.25% 6% 5.6% 5.51% 4.89% 5.21%
Announcement Date 25/04/19 27/04/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,415 JPY
Average target price
5,853 JPY
Spread / Average Target
+8.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.06% 69TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 59TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 36TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+4.27% 29TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 24TCr
NOVARTIS AG Stock Novartis AG
+10.16% 21TCr
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 20TCr
AMGEN INC. Stock Amgen Inc.
+8.12% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock
  5. Financials Daiichi Sankyo Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW